| Investor | Vestal Point Capital, LP |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Vestal Point Capital, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2025-08-14 |
|
QURE / uniQure N.V. | 4,792,572 | 3,700,000 | ||||
| 2025-08-14 |
|
NYXH / Nyxoah SA | 2,318,954 | 1,402,002 | ||||
| 2025-08-14 |
|
BCAX / Bicara Therapeutics Inc. | 2,768,975 | 5,000,000 | ||||
| 2025-08-14 |
|
LXEO / Lexeo Therapeutics, Inc. | 3,228,161 | |||||
| 2025-08-14 |
|
DNTH / Dianthus Therapeutics, Inc. | 1,700,069 | 3,200,000 | ||||
| 2025-05-15 |
|
TYRA / Tyra Biosciences, Inc. | 2,879,829 | |||||
| 2025-05-15 |
|
QURE / uniQure N.V. | 3,025,000 | 4,792,572 | ||||
| 2025-05-15 |
|
BCAX / Bicara Therapeutics Inc. | 2,768,975 | |||||
| 2025-05-15 |
|
DNTH / Dianthus Therapeutics, Inc. | 1,700,069 | |||||
| 2025-05-15 |
|
SLDB / Solid Biosciences Inc. | 2,800,000 | 1,753,558 | ||||
| 2025-05-15 |
|
NYXH / Nyxoah SA | 2,924,216 | 2,318,954 | ||||
| 2025-02-14 |
|
APLT / Applied Therapeutics, Inc. | 1,145,000 | 11,500,000 | ||||
| 2025-02-14 |
|
SVRA / Savara Inc. | 10,775,000 | |||||
| 2025-02-14 |
|
QURE / uniQure N.V. | 4,750,000 | 3,025,000 | ||||
| 2025-02-14 |
|
NYXH / Nyxoah SA | 2,924,216 | |||||
| 2025-02-14 |
|
IMTX / Immatics N.V. | 6,275,000 | |||||
| 2024-11-14 |
|
ATXS / Astria Therapeutics, Inc. | 4,000,000 | |||||
| 2024-11-14 |
|
BDTX / Black Diamond Therapeutics, Inc. | 5,028,500 | |||||
| 2024-11-14 |
|
KALV / KalVista Pharmaceuticals, Inc. | 4,000,000 | |||||
| 2024-11-14 |
|
PASG / Passage Bio, Inc. | 6,100,000 | |||||
| 2024-11-14 |
|
SLDB / Solid Biosciences Inc. | 2,800,000 | |||||
| 2024-11-14 |
|
QURE / uniQure N.V. | 3,925,000 | 4,750,000 | ||||
| 2024-11-14 |
|
APLT / Applied Therapeutics, Inc. | 4,155,000 | 1,145,000 | ||||
| 2024-11-14 |
|
LYRA / Lyra Therapeutics, Inc. | 3,000,000 | 0 | ||||
| 2024-02-13 |
|
APLT / Applied Therapeutics, Inc. | 4,155,000 | |||||
| 2024-02-13 |
|
QURE / uniQure N.V. | 3,925,000 | |||||
| 2024-02-13 |
|
LYRA / Lyra Therapeutics, Inc. | 3,000,000 |
